SIGN UP

Evan Feinberg, CEO of Genesis Therapeutics (Boris Feldman)

May 3, 2022 10:40 AM EDTUpdated May 3, 11:02 PM

Genentech-partnered Genesis Therapeutics inks newest AI discovery deal with Eli Lilly

Paul Schloesser

Associate Editor

A Stanford biotech rubbed elbows with Genentech in 2020, reaching a deal with the big-name biotech just over 18 months ago. And now, the AI …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

sponsored

Are programs with compounded GLP-1s safe for your population?